Is CBD Right For Your Dog?
Kimberley Pike couldn’t believe her eyes. In the span of just a few hours, Zoey, her German Shepherd—who has mobility issues and possible arthritis—had gone from moving slowly and painfully, to playing with Kimberley’s three other German Shepherd Dogs.
“At first, Zoey was given Metacam to help ease her pain, but I wasn’t happy with the results,” says Kimberley, who lives in Spaniard’s Bay, NL. “It did ease her pain but she seemed sleepy all the time. I did some research on medications, but all had side effects that I wasn’t comfortable with.”
When Kimberley’s dog groomer told her about the benefits of CBD oil, she began her research, administering Zoey’s first dose in October 2018.
“Within a couple of hours, I could see a change in Zoey,” says Kimberley. Zoey, now seven years old, started behaving like a puppy again. “She looked so happy. No whining or moaning or struggling to get up. Within a couple of days, she was up and down our stairs with ease.” The cloudiness in Zoey’s eyes also cleared up, something Kimberley also attributed to CBD.
Kimberley is just one of many pet owners turning to cannabidiol—more commonly known as CBD—to treat their dogs’ ailments.
CBD products for pets have become increasingly popular, confirms Dr. Katherine Kramer, medical director for VCA-Canada Vancouver Animal Wellness Hospital, a small animal integrative hospital in Vancouver, B.C. And for good reason. Dogs are highly sensitive to THC, or tetrahydrocannabinol—which is the principal psychoactive component of marijuana—but CBD is derived from hemp and is non-psychoactive.
“There is increasing evidence that CBD can be helpful for pets with arthritis or chronic pain, cancer, seizures, and some behavioural issues, such as anxiety, cognitive impairment,” says Dr. Kramer, who is also a director of the Canadian Association of Veterinary Cannabinoid Medicine. “There are many companion animal research projects currently looking into the benefits of cannabis. As we learn more about how these products interact with the endocannabinoid system, we should find even more indications for their use.” As with any treatment, the decision as to why and when to use a product should be discussed with your vet, says Dr. Kramer. “Your veterinarian should always be your first resource for any health question that involves your pet,” she says. “CBD (as well as other supplements) can potentially interact with many medications, so your veterinarian needs to know.”
Over the years, Dr. Kramer has had numerous patients on various cannabis products. “The majority of dogs (and cats) have amazing responses,” she says. “Many pet parents turned to CBD when conventional medicine was not providing relief. Many of my clients have told me that ‘CBD gave us our dog back’.”
A New Leash on Life
12-year-old Shih Tzu-Maltese mix Frankie William is one of these dogs. Frankie has a twisted spine and bad hip and knee, as well as anxiety. When his owner, Toronto, ON resident Laura Lockhart, administered CBD oil she noticed a difference immediately. “It was like his energy calmed and he was back to his old self. He’s doing ‘zoomies’ again, playing with his toys and going up and down his ramp (to the bed). It’s like he’s young again. I love it.” She has since been giving him two to three drops a day, as per the vet’s directions.
Vet guidance is important, emphasizes Dr. Kramer. “Working with cannabis products has given me another option for therapy, to treat pain and discomfort, to provide palliative care. I can’t imagine practising without it.”
Despite being hemp-derived, CBD is legal throughout Canada and in all US states. As CBD becomes more widely accepted, more people are looking to try it for their pets.
Before using it on her dog, Lynne Kaska described herself as “anti-CBD.” Her love for her service dog,
a Catahoula mix named Reese, convinced the Dallas, TX-area resident to give it a try.
Reese suffered from irritable bowel syndrome, atypical Addison’s disease, and patella luxation (for which he has had surgery). After two years of battling lack of appetite, vomiting, nausea, lethargy, and diarrhea, and trying countless remedies (including trying B12 injections to stimulate his appetite and energy) with no real success, Lynne contemplated retiring him. Then she tried CBD oil. The oil in addition to the prednisone he was taking improved Reese’s symptoms immensely.
“Within two weeks, people were telling me what a huge difference they saw in him,” says Lynne. “I slowly started reintegrating him into public settings. He doesn’t tuck his tail as much as he used to and his shaking when he’s nervous has dramatically improved. He gained 40 pounds in six months and nearly doubled in size in what Lynne calls a “miraculous” recovery.
Ryker, a three-and-a-half-year-old silver Labrador Retriever, takes CBD for epilepsy, which he developed at seven months. At 14 months old, Ryker’s owner, Kim Stover-Dowidait, changed his diet and started him on CBD oil as an alternative to some of the seizure medications on the market that have some side effects. “His seizures diminished from weekly to having one a month,” says Kim. “At one time he went seizure free for eight months. It was a lifesaver for us. He has so far stayed off all meds, just relying on a good third-party-tested oil.”
CBD also helps inflammation. Two-year-old Labrador Retriever mix Leeloo was on Prednisone for three months, only to have the inflammation return a few months later. Her owner, Malena Sweeney, didn’t want to put her back on steroids due to the side effects, and so she decided to give CBD oil a try. “Within a week her eyes were back to normal, and it hasn’t been back since.”
Owner Jenn Grenier also saw fast results for her dog Sprocket, a nine-year-old female Boxer/Pit mix diagnosed with intervertebral disc disease, arthritis, and bilateral elbow disease. She was on NSAIDs, nerve medication, and narcotics which helped with the pain, but can also be damaging to the kidneys and liver and would alter Sprocket’s personality. Jenn, an Upton, MA resident, began looking at alternative medicine and learned about Canna-Pet, a company making CBD products for pets. She “initially thought it was too good to be true. How can one product help so many ailments?”
After only a week, Sprocket was well enough that Jenn felt confident enough to bag up the heavy-duty medications and put them away. “Going on three years of taking it, my senior dog is happy, healthy, and pain free,” says Jenn.
All of these dogs have something in common—their canine lives have been changed by CBD oil.
“This oil has changed our girl’s life and ours too,” says Kimberley of Zoey. “She is a totally different dog since this oil—whining has stopped, moaning has stopped. She moves with ease around our home. She’s back to being active, swimming and hiking.” The only issue now, she says, is to keep Zoey from running and jumping too much. “Because of her arthritis, I wouldn’t want her to hurt herself,” Kimberley says. “But she definitely feels like she can do it. My Zoey is not in pain anymore and she’s happy. That makes me happy too.”
Interested in giving CBD a try?
We’ve rounded up a selection of providers offering CBD treats and oils formulated especially for dogs.
Green Roads’ CBD Drops blend hemp-derived cannabinoid extracts with MCT oil to help promote calmness and decrease anxiety from stressful situations like vet visits, and thunderstorms. (From $20, greenroadsworld.com)
Iceland Pure’s Next Level Premier CBD Fish Oil’s unique formula combines CBD oil with fish oils for a high absorption rate, relieving anxiety, lubricating joints, bolstering immunity, and helping battle cancer. (From $82, icelandpure.com)
Extra Strength Health Drops from Healthier Pet combine 99.2% pure CBD isolate with organic hemp oil and fish oil for an added health boost. Designed to work quickly, they help treat an array of aliments. (From $53, healthierpet.org)
Blue Ridge Botanicals’ Doggie Drops & Kitties Too offers broad spectrum CBD derived from organic hemp with MCT oil, delivering the strong anti-inflammatory properties, pain relief, and seizure control associated with cannabinoids. (From $15, blueridgebotanicalsco.com)
Bakko’s Get Up and Go CBD biscuits from Austin and Kat are made with New Zealand green mussel, glucosamine, and full-spectrum CBD oil to repair and support joint health. (From $50, austinandkat.com)
Suzie’s CBD pet treats are full spectrum, human-grade, and organic—the hemp is grown on their own USDA organic farm—providing the benefits of CBD in a treat form that dogs can’t resist. ($20, suziespettreats.com)
Pet Essentials Peanut Butter CBD treats from Oliver’s Harvest deliver the benefits of hemp-derived cannabidiol with a sweet peanut-butter taste your dog will love, making this a daily routine you’ll both enjoy. (From $24, oliversharvest.com)
All-natural Balancing Bites from Pawse are made with premium broad-spectrum CBD hemp extract, fish oil, plant-derived terpenes, and real chicken, making overall wellness easy for dogs of all sizes. ($39, pawse.pet)
Marijuana Use and Hypothalamic-Pituitary-Adrenal Axis Functioning in Humans
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Preclinical studies suggest cannabinoids affect functioning of the hypothalamic-pituitary-adrenal (HPA) axis, but little is known about the effects of marijuana (MJ) use on HPA axis functioning in humans. Since previous work indicates substances of abuse may dysregulate the HPA axis, it is critical to understand how MJ use affects HPA axis activity. Here, we review studies that (a) examined the effects of acute MJ administration on HPA axis functioning, (b) investigated the impact of stress on HPA axis functioning in MJ users, (c) examined the effect of chronic MJ use on basal cortisol levels, and (d) studied the relationship between MJ use and the cortisol awakening response (CAR). Findings indicate acute MJ administration typically raises cortisol levels, but this increase is blunted in MJ-dependent users relative to controls. Frequent MJ users have blunted adrenocorticotropic hormone and cortisol reactivity in response to acute stress. These findings suggest HPA axis activity may be dysregulated by heavy MJ use. Alternatively, dysregulation of the HPA axis may be a risk marker for heavy MJ use. There is mixed evidence for how MJ use affects basal cortisol levels and the CAR. Future studies should consider MJ use characteristics, method of hormone collection, time when samples are collected, and environmental factors that may influence HPA axis activity in MJ users. By examining existing studies we provide one of the first reviews aimed at synthesizing the literature on HPA axis functioning in MJ users.
Keywords: marijuana, hypothalamic-pituitary-adrenal axis, cortisol, adrenocorticotropic hormone, tetrahydrocannabinol
Marijuana (MJ) is the most commonly used illicit substance worldwide, with ~147 million past year users (1). Within the United States, MJ use has significantly increased during the past decades. Between 2001 and 2002, 4.1% of adults reported past year MJ use compared to 9.5% between 2012 and 2013, 30% of whom met criteria for cannabis use disorder (2). These increases in MJ use coincide with a time of MJ decriminalization, legalization, and changing attitudes regarding risk of MJ use (3). While multiple risk factors contribute to heavy MJ use, cumulative stress is one pathway that may be linked to chronic MJ use as individuals report using MJ to reduce stress (4).
Several studies indicate that the hypothalamic-pituitary-adrenal (HPA) axis, the major neuroendocrine system that responds to stress (5), is dysregulated in substance users (6, 7). In response to acute stress as well as substances of abuse, the HPA axis releases corticotropin-releasing hormone (CRH) from the hypothalamus, which promotes release of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland, ultimately resulting in cortisol secretion from the adrenal cortex. However, chronic stress and heavy substance use can lead to allostatic load, HPA axis dysfunction, and adverse effects on stress responsivity (8, 9). Despite the worldwide prevalence of MJ use, little is known about HPA axis response in heavy MJ users. Understanding how MJ use affects HPA axis functioning in humans is critical to informing studies on the role of the neuroendocrine stress system in chronic MJ users and in individuals at risk for heavy MJ use.
The purpose of this review is to provide a descriptive overview of prior research on the effects of acute MJ administration on HPA axis activity, the impact of stress on HPA axis functioning in MJ users, and the role of chronic MJ use on basal cortisol levels and the cortisol awakening response (CAR). Additionally, we compare methodological differences among studies that may have contributed to discrepant findings, and comment on future directions for advancing research in this field. Articles for this mini review were included based on combinations of keywords searched on Pubmed, including “marijuana”, “HPA axis”, “cortisol”, “tetrahydrocannabinol (THC)”, and “endocannabinoid.” Titles and abstracts were reviewed for relevance to the topic on human MJ users. Additional articles were found through citations included within the manuscripts found using the keyword search.
Effects of THC administration and acute marijuana use on HPA axis functioning in marijuana users
Several studies have investigated the effects of acute MJ administration on HPA axis response by examining ACTH and/or cortisol levels in a laboratory setting (Table (Table1). 1 ). Cone et al. (11) found that MJ administration raised serum cortisol levels in MJ users compared to baseline. Similar results were reported by Kleinloog et al. (15), who reported that THC inhalation increased cortisol compared to baseline in infrequent MJ users. These findings were replicated in a resting state functional magnetic resonance imaging (fMRI) study, such that THC administration elevated cortisol levels compared to placebo in MJ users, but as there were no changes in hypothalamic connectivity observed, cortisol levels were not examined in relation to functional connectivity (16). In another study, De souse Fernades perna et al. (17) examined the effects of vaporized THC administration on cortisol response before and after an implicit association task displaying aggressive behavior, in which participants self-reported how aggressive they felt after viewing each image. MJ administration significantly elevated cortisol levels compared to placebo prior to aggression exposure. Cortisol levels were also higher after inhalation of MJ vs. unintoxicated baseline levels in an fMRI study examining the aphrodisiacal effects of MJ in MJ users. However, there were no differences in cortisol levels between MJ users with or without prior aphrodisiacal experiences, so its effect on brain activity was not examined further (18). Considering the lack of standardization of MJ administration, caution should be used when drawing conclusions based on these results. Overall, increases in cortisol after MJ administration may have both advantageous and disadvantageous effects. For example, as HPA axis activity mobilizes the body to face challenges, increased cortisol levels could be related to enhanced attention after acute MJ administration in heavy users (35), but could also be associated with impairments in other cognitive domains, such as working memory and inhibition (35), and increased anxiety (36). Thus, the increased cortisol response may be beneficial in certain contexts, but detrimental in others.
Studies of HPA axis functioning in marijuana users.
|Study||Participants||Sample size||Age (mean ±SD)||Study design||ACTH or cortisol analysis||Main findings|
|ACUTE MJ ADMINISTRATION STUDIES|
|Benowitz et al. (10)||Regular MJ users (only male users)||n = 6||21–30||210 mg oral THC for 14 days,.15 U/kg IV insulin||Plasma cortisol||No acute effect of THC on cortisol; following THC treatment, insulin administration ↓ cortisol compared to pre-THC treatment levels|
|Cone et al. (11)||Frequent MJ users (only male users)||n = 4||33.75 a||Inhaled 2 MJ cigarettes (2.8% THC), 1 MJ and one placebo cigarette, or 2 placebo cigarettes (one condition per day)||Plasma cortisol||↑ cortisol compared to baseline|
|Dax et al. (12)||Abstinent heavy and occasional MJ users (only male users)||n = 7 oral THC
n = 6 inhaled THC
n = 5 placebo
|Age statistics not reported||10 mg oral THC (Marinol) or 18 mg/1.2 g inhaled MJ cigarette for 3 days (once on day 4)||Plasma ACTH and cortisol||No effect on cortisol for either method of administration|
|D’ Souza et al. (13)||Abstinent MJ-dependent users and HC||n = 30 MJ users
n = 22 HC
|MJ = 24.8 ± 5.5
HC = 29 ± 11.6
|0, 2.5, or 5 mg IV THC (one condition per day, test days separated by ≥1 week)||Plasma cortisol||Dose-dependent ↑ cortisol compared to placebo, blunted in frequent MJ users|
|Ranganathan et al. (14)||Abstinent MJ-dependent users and HC||n = 40 MJ users
n = 36 HC
|MJ = 28.28 ± 10.2
HC = 24.58 ± 4.9
|Study 1: Placebo, 0.0357 mg/kg, 0.0714 mg/kg IV THC Study 2: placebo, 0.0286 mg/kg IV THC||Serum cortisol||Dose-dependent ↑ cortisol, blunted in frequent MJ users|
|Kleinloog et al. (15)||Mild MJ users (only male users)||n = 49 mild MJ users||18–45||2-, 4-, and 6 mg inhaled THC at 90 min intervals||Serum cortisol||↑ cortisol compared to baseline|
|Klumpers et al. (16)||Occasional MJ users||n = 12||22.17 ± 2.95||Day 1: 3 doses placebo Day 2: 2, 6, and 6 mg inhaled THC||Serum cortisol||↑ cortisol compared to placebo|
|De Sousa Fernandes Perna et al. (17)||Regular MJ users; heavy alcohol users; HC||n = 21 regular MJ users
n = 20 alcohol users
n = 20 HC
|MJ = 21.9 ± 2.2
Alcohol = 22.7 ± 2.4
HC = 22.9 ± 2.3
|300 μg/kg vaporized MJ (12% THC), aggression implicit association task (IAT)||Serum cortisol||↑ cortisol compared to placebo in MJ users administered THC prior to IAT|
|Androvicova et al. (18)||Casual MJ users||n = 12 aphrodisiac
n = 9 non-aphrodisiac
|Aphrodisiac = 29.08 ± 5.37
Non-aphrodisiac = 23.78 ± 3.03
|Inhaled socially relevant doses of personal MJ 30 min prior to study visit||Serum cortisol||↑ cortisol compared to baseline|
|Childs et al. (19)||occasional MJ users, ≤ 1 use per week||n = 14: 0 mg THC
n = 15: 7.5 mg THC
n = 13: 12.5mg THC
|0 mg THC = 23.8 ± 1.4
7.5 mg THC = 23.2 ± 0.9
12.5 mg THC = 23.9 ± 1.3
|0, 7.5, or 12.5 mg oral THC (Marinol), Trier Social Stress Task||Salivary cortisol||No effect of THC on pre- or post- TSST cortisol levels|
|STRESS ADMINISTRATION STUDIES|
|Van Leeuwen et al. (20)||Lifetime abstainers; lifetime tobacco users; and lifetime MJ users; users were also classified as repeated or lifetime users only||n = 219 lifetime abstainers
n = 168 lifetime tobacco users
n = 204 lifetime MJ users
|16.27 ± 0.73||Groningen Social Stress Test||Salivary cortisol||↓ cortisol in lifetime MJ users vs. lifetime abstainers or lifetime tobacco users; similar finding in repeated MJ users vs. lifetime MJ or tobacco only users|
|Mcrae-Clark et al. (21)||MJ-dependent||n = 87||MJ stress group = 25.5 ± 9.2 MJ no stress group = 26.2 ± 8.0||Trier Social Stress Task; MJ cues||Plasma ACTH and cortisol||↑ ACTH and cortisol in stress group; ↑ cortisol in response to neutral vs. MJ cues|
|Somaini et al. (22)||Active MJ-dependent; abstinent MJ-dependent; HC||n = 14 MJ-dependent
n = 14 abstinent MJ-dependent
n = 14 HC
|MJ = 24.1 ± 2.7
HC = 25.4 ± 3.6
|Unpleasant and neutral pictures from IAPS||Plasma ACTH and cortisol||Active MJ-dependent ↑ basal ACTH and cortisol vs. other groups, but smallest ↑ in ACTH and cortisol after viewing unpleasant images|
|Fox et al. (23)||Treatment-seeking MJ, alcohol, cocaine dependent; alcohol/cocaine dependent; social drinking HC||n = 30 MJ, alcohol, cocaine- dependent
n = 29 alcohol, cocaine- dependent
n = 26 social drinking HC
|MJ/alcohol/cocaine = 33.7 ± 6.9
alcohol/cocaine = 37.1 ± 6.4
HC = 28.1 ± 1.4
|Guided imagery (stress, alcohol/cocaine cue, relaxing)||Plasma ACTH and cortisol||MJ-dependent polysubstance users ↑ ACTH and cortisol to stress vs. relaxing imagery; effect not seen in other groups|
|Tull et al. (24)||MJ-dependent PTSD; MJ-dependent no PTSD, PTSD only; no PTSD/no MJ-dependence||n = 18 PTSD/MJ
n = 32 MJ no PTSD
n = 27 PTSD only
n = 91 no PTSD/no MJ
|34.32 ± 10.1||Trauma cues||Salivary cortisol||No effect of trauma cues on cortisol|
|Cuttler et al. (25)||Daily or near-daily MJ users; HC||n = 40 daily MJ users
n = 42 HC
|MJ users in stress condition = 26.05 ± 1.44
MJ users in no stress condition = 25.14 ± 1.86
HC in stress condition = 26.95 ± 2.23
HC in no stress condition = 25.24 ± 1.19 b
|Maastricht Acute Stress Test||Salivary cortisol||↓ cortisol in daily MJ users vs. HC|
|Nusbaum et al. (26)||Daily or near-daily MJ users; HC||n = 39 daily MJ users
n = 40 HC
|MJ users in stress condition = 25.85 ± 6.19
MJ users in no stress condition = 25.35 ± 8.71
HC in stress condition = 27.25 ± 10.4
HC in no stress condition = 25.25 ± 5.57
|Maastricht Acute Stress Test||Salivary cortisol||↓ cortisol in daily MJ users vs. HC|
|Chao et al. (27)||Non-treatment seeking daily MJ users with and without trauma exposure||n = 125||Age range 18–50 (more detailed demographics of the six subgroups in table of manuscript)||Trier Social Stress Task||Salivary cortisol||↑ cortisol before, during, after TSST in daily MJ users with trauma exposure vs. daily MJ users without trauma exposure|
|BASAL CORTISOL STUDIES e|
|Block et al. (28)||Frequent, moderate, infrequent, or non-Users of MJ||n = 27 frequent MJ users
n = 18 moderate MJ users
n = 30 infrequent MJ users
n = 74 non-users
|23.5 ± 0.4 b , more detailed demographics divided by user group and sex in table of manuscript||Morning or afternoon blood draw||Serum cortisol||No difference between groups|
|King et al. (29)||Daily or near daily MJ users; HC||n = 30 MJ users
n = 30 HC
|M MJ users = 21
F MJ users = 22.5
M HC = 23
F HC = 24.5 d
|Morning saliva collection||Salivary cortisol||↑ cortisol in MJ group compared to HC|
|Cloak et al. (30)||Heavy MJ users; light MJ users; HC||n = 43 heavy MJ users
n = 37 light MJ users
n = 42 HC
|Heavy MJ users = 19.4 ± 0.3
Light MJ users = 19.1 ± 0.4
HC = 18.3 ± 0.4 c
|Late morning or afternoon saliva collection f||Salivary cortisol||No difference between groups|
|Carol et al. (31)||UHR youth with current MJ use; UHR youth without current MJ use; HC||n = 17 UHR with MJ use
n = 26 UHR without MJ use
n = 29 HC
|UHR with MJ use = 19.59 ± 0.87
UHR without MJ use = 18.46 ± 1.92
HC = 17.34 ± 2.82
|Three saliva samples every 60 min between 8:45 a.m.−2 p.m.||Salivary cortisol||↑ cortisol in MJ group compared to HC|
|Lisano et al. (32)||Physically active regular MJ users; physical active HC (males only)||n = 12 regular MJ users
n = 12 HC
|MJ = 23.33 ± 4.14
HC = 24.08 ± 5.5
|Blood samples collected between 7 and 9 a.m.||Serum cortisol||No difference between groups|
|CORTISOL AWAKENING RESPONSE STUDIES|
|Huizink et al. (33)||Early (9–12 years old), late (13–14 years old), and non-users of MJ||n = 59 late MJ users
n = 44 early MJ users
n = 1338 non-users
|Cortisol collected between ages 10 and 12, age breakdown for groups not reported||Saliva collected at awakening, 30 min later, and 8 pm||Salivary cortisol||↓ cortisol 30 min post-awakening in early MJ users vs. late MJ users; MJ users ↑ evening cortisol vs. non-users|
|Montelone et al. (34)||SCZ with MJ use prior to psychotic symptoms; SCZ with no MJ use prior to psychotic symptoms; HC||n = 16 SCZ with MJ use
n = 12 SCZ without MJ use
n = 15 HC
|SCZ with MJ use = 39.1 ± 7.2
SCZ without MJ use = 43.6 ± 7.3
HC = 37.6 ± 6.9 c
|Saliva collected at awakening, and 15, 30, and 60 min later||Salivary cortisol||↑ baseline cortisol in SCZ with MJ use vs. HC; ↓ CAR in SCZ with MJ use vs. HC|
ACTH, adrenocorticotropic hormone; CAR, cortisol awakening response; HC, healthy controls; IV, intravenous; MJ, marijuana; PTSD, post-traumatic stress disorder; SCZ, schizophrenia; THC, tetrahydrocannabinol; TSST, Trier Social Stress Task; UHR, ultra-high risk; ↑, increase/increased/greater; ↓, decrease/decreased/less.
e As there was no specific drug administration or acute stress manipulation, study design refers to time of day for blood or saliva samples to measure basal cortisol levels.
f A subset of participants completed the TSST and computerized neuropsychological battery and saliva was also collected before and after these tests, but no effects were found.
In other studies, cortisol levels were compared between abstinent MJ-dependent individuals and non-users following intravenous THC administration. MJ-dependent individuals exhibited a blunted cortisol increase after THC administration compared to non-users (13, 14). Preclinical research has linked this blunted cortisol response to MJ tolerance (37), while other research suggests differences in MJ response may be influenced by genetics (38).
Some studies have found no significant effect of acute MJ administration on cortisol levels. In a study conducted by Benowitz et al. (10), the effects of insulin-induced hypoglycemia in MJ users were examined. Participants were given insulin prior to and after oral THC was administered. No difference in cortisol was observed between baseline and post-THC treatment but insulin administration decreased cortisol compared to pre-THC treatment levels. In a study by Dax et al. (12) abstinent MJ users were administered oral or inhaled THC. No differences were observed in ACTH or cortisol between baseline and post-treatment levels. Small sample sizes may have resulted in the lack of significant findings in these studies. Childs et al. (19) also found no relationship between acute administration of oral THC and cortisol response. The authors suggest their lack of findings could have been the result of collection of salivary rather than serum cortisol, the latter possibly being a more sensitive measure of cortisol. Moreover, in studies that found no effect of MJ on cortisol levels, greater time elapsed between MJ administration and cortisol assessment. It is possible the acute effects of MJ on cortisol could have diminished before cortisol assessment. Since studies that found an association between acute MJ administration and HPA axis response collected cortisol samples closer to the time of acute MJ use, it may be necessary for future studies to measure cortisol within 2 h following MJ administration. In sum, the majority of research examining acute MJ administration on cortisol reactivity has indicated MJ significantly increases cortisol, and some studies report that abstinent MJ-dependent users show a blunted increase in cortisol relative to non-users.
Effects of stress on HPA axis functioning in marijuana users
A number of studies in MJ users have examined the effects of acute stressors on HPA axis activity (Table (Table1). 1 ). A study by Somaini et al. (22) presented neutral and unpleasant images to MJ-dependent individuals, abstinent MJ-dependent individuals, and healthy controls. Interestingly, active MJ users had generally high basal stress hormone levels but reduced responsivity of the HPA axis, potentially due to dysregulation of the stress system by MJ use. These findings are in contrast to another study in which MJ-dependent polysubstance users had significantly higher levels of plasma cortisol and ACTH following exposure to stress imagery relative to relaxing imagery, a finding not present in non-MJ-dependent polysubstance users or social drinkers (23). Since participants in this study were abstinent treatment-seeking polysubstance users, the elevated cortisol and ACTH levels could reflect a “rebound” upregulation of the HPA axis following abstinence (23).
Two recent studies examined salivary cortisol in chronic adult MJ users using the Maastricht Acute Stress Test, which includes both physiological stress (placing hand in ice water) and psychosocial stress (solving math problems). The acute stress manipulation resulted in blunted cortisol response in the daily MJ users compared to healthy controls (25, 26). For individuals who may be characterized by an overactive HPA axis, a reduction in cortisol activity may be beneficial. Alternatively, cortisol release usually serves to motivate adaptive responses during stressful situations and a blunted response could impair one’s ability to act appropriately (8, 25). In particular, a blunted cortisol response to psychosocial stress has been associated with anxiety and depression in women (39), suggesting female MJ users may be at increased risk for anxiety and depression symptoms. Similar findings were reported in a study with a large sample (N = 591) of adolescent MJ users who had lifetime or repeated MJ use (20). The authors reported lower salivary cortisol levels during the Groningen Social Stress Task (involving both a speech and math problems) in adolescents who had ever used MJ relative to non-users or participants who reported lifetime tobacco use. This finding was also seen when the authors compared adolescents who used MJ at least five times in the past year with lifetime users of MJ or tobacco. These results were interpreted as a reduction in HPA axis response in adolescents who are at risk for using MJ repeatedly, possibly to stimulate their HPA axis response. Finally, another study that utilized the Trier Social Stress Task found that stress increased plasma ACTH and cortisol levels in MJ-dependent participants (21). However, in response to MJ cues, cortisol levels were significantly lower in MJ-dependent participants than in response to neutral cues. As the purpose of this study was to examine the effects of stress and drug cues on physiological reactivity in MJ-dependent individuals, no control group was included.
Other types of stress, such as previous trauma exposure, which may influence cortisol response in MJ users, was examined in a study of non-treatment seeking daily MJ users (27). Daily MJ users who experienced trauma had higher overall cortisol levels before, during, and after the Trier Social Stress Task than those who had never experienced trauma. However, as there was no control group of non-using participants in this study, it is uncertain whether the effects of trauma on cortisol reactivity would be similar to or different from the daily MJ users. Contrary to the findings of this study, Tull et al. (24) found no effects on cortisol reactivity in participants with or without post-traumatic stress disorder who were either MJ-dependent or non-dependent, even though MJ-dependent participants reported less subjective emotional reactivity in response to trauma cues.
Taken together, the findings to date suggest that stress exposure in adult heavy MJ users (22, 25, 26), or adolescents at risk for heavy MJ use (20) is mostly related to blunted reactivity of the HPA axis. This could suggest both dysregulation as result of MJ use or increased vulnerability toward frequent MJ use as individuals may engage in MJ use to increase responsivity of an underactive HPA axis. As there is currently limited research in this area, future studies should carefully consider the following variables, which could impact study findings: method of obtaining cortisol sample [plasma: (21–23) vs. saliva: (20, 24, 25, 27)], time of day of cortisol measurement, duration of time between stress administration and cortisol measurement, MJ use criteria (frequency of use, MJ-dependent or non-dependent sample, treatment seekers vs. non-treatment seekers), and co-occurring mental health conditions, such as previous trauma exposure (24, 27) or psychopathology (23).
Marijuana use and basal HPA axis activity
Studies have measured cortisol levels in frequent MJ users and non-users to determine whether the groups differ in basal cortisol levels, and findings suggest MJ has either no effect or increases basal cortisol (Table (Table1). 1 ). Block et al. (28) found that there was no difference in serum cortisol levels between frequent, moderate, and infrequent MJ users and controls. However, only one blood sample was taken and time of day for blood draws varied among participants. There was also no difference in serum cortisol response in physically active MJ-using adults compared to non-using controls, suggesting that heavy MJ use may not affect stress hormone levels in individuals with high levels of physical activity (32). Since previous studies report that MJ may be used to reduce stress and anxiety symptoms (4), Cloak et al. (30) examined the relationship between MJ use, anxiety symptoms, and cortisol levels in adolescent and young adult heavy, light, and non-MJ users. There was no effect on mid-day salivary cortisol despite greater MJ use being associated with more anxiety symptoms, indicating a disconnect between psychological, and physiological stress reactivity.
Contrary to the findings above, an fMRI study examining psychomotor function found that chronic MJ users had higher levels of salivary cortisol compared with controls and greater superior frontal gyrus (SFG) but reduced visuomotor activity relative to controls (29). The authors propose that this increased cortisol in MJ users may impair visuomotor function during psychomotor tasks, resulting in greater reliance on brain regions involved in attention and motor planning, such as the SFG. A recent study of adolescents at ultra-high risk for schizophrenia reported that youth who used MJ in the past month had higher levels of salivary cortisol than healthy controls, suggesting a potential link between risk for psychosis and HPA axis functioning (31). Previous research indicates high basal cortisol levels are associated with hypertension and obesity (40), as well as hippocampal atrophy and memory impairment in aging populations (41). The potential effect of frequent MJ use on basal cortisol levels requires further investigation to clarify inconsistencies in the literature. Variations in participant characteristics, MJ use parameters, and method of cortisol assessment may have contributed to the inconsistent findings.
Cortisol awakening response in marijuana users
Cortisol levels exhibit diurnal variation, such that levels rise during the morning hours, peak 30 min after awakening, and are lowest in the evening. This increase of cortisol in the morning, known as the CAR is believed to be a reliable marker for individual differences in HPA axis activity (42). Studies have reported that the CAR is influenced by substance use, such as heavy alcohol use (43, 44). Surprisingly, little is known about the CAR in MJ users (Table (Table1). 1 ). To our knowledge, only one study to date has examined diurnal cortisol response in MJ users, and found blunted levels of cortisol 30 min after awakening in a large sample of children (10–12 years old) who began using MJ during early adolescence (9–12 years old) relative to those who initiated use in later adolescence (13–14 years old) (33). These findings may indicate that blunted cortisol response could be a risk factor for initiating MJ use. The study also found that participants who initiated MJ use regardless of age at first use, had higher levels of evening cortisol relative to non-users. The authors believed this finding may be explained more by environmental influences on cortisol levels in the evening, such as ongoing stressful events rather than genetic vulnerability toward MJ use. Similar findings were reported in another study, albeit in a sample of participants diagnosed with schizophrenia who were also MJ users (34). These participants had higher baseline levels of cortisol, but a flattened CAR relative to healthy controls. These findings may indicate that MJ use in schizophrenics contributes to dysregulation of the HPA axis, although it is possible that blunted CAR in MJ-using schizophrenics predated and increased their vulnerability toward substance use. Given the lack of research investigating the CAR in MJ users, significant work is needed to characterize how MJ use affects the CAR and whether dysregulation of HPA axis functioning is a risk factor for and/or further drives MJ use.
Conclusions and future directions
The purpose of the current mini review is to highlight and integrate the existing, albeit limited literature on the effects of MJ use and stress on HPA axis functioning in adult MJ users and youth at risk for heavy MJ use. Understanding these findings comes at an important time when MJ decriminalization and legalization has made MJ increasingly available, while the perceived risk of MJ use has declined (3). Preclinical research has indicated that cannabinoids affect functioning of the HPA axis [for review, see Steiner and Wotjak (45)], and it appears that the current findings suggest that overall, acute MJ administration elevates cortisol levels, but to a smaller degree in MJ-dependent users. Further, acute stress exposure in heavy MJ users also appears to largely blunt cortisol reactivity. The findings on basal cortisol levels are mixed, likely due to diurnal fluctuations of cortisol and because cortisol is sensitive to changes in daily stress. These findings suggest that MJ use may dysregulate normal functioning of the HPA axis, perhaps as individuals develop tolerance to MJ, which could further drive MJ use. An alternative explanation is that individuals at risk for MJ use seek out MJ to stimulate an underactive HPA axis. Further research, including longitudinal studies of MJ users to examine long-term effects on HPA axis functioning are needed. While there is a growing literature on the effects of MJ use on brain structure and functioning in humans (46, 47), few studies have measured HPA axis activity in neuroimaging studies of MJ users, an important avenue for future research. This could provide information on how biological markers related to stress reactivity are associated with neurocognition in MJ users. Additionally, to our knowledge only two studies have examined the CAR in MJ-using participants, thus necessitating significant work in understanding how MJ use affects diurnal HPA axis rhythms. Work is currently underway in our laboratory to examine the effects of adult heavy MJ use on the CAR.
All authors contributed to the article search for this review. AC and JD-B wrote the Introduction, SL wrote the section on acute THC and MJ effects on HPA axis functioning, and AC wrote the sections on stress, basal cortisol, cortisol awakening response, and conclusions and future directions. AC and SL created the table. AC edited and finalized the manuscript.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This work was supported by the Oregon State University Center for Humanities and College of Liberal Arts Research Grant to AC.
1. World Health Organization . Cannabis (2018). Available online at: http://www.who.int/substance_abuse/facts/cannabis/en/ (Accessed June 7, 2018).
2. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. . Prevalence of marijuana use disorders in the united states between 2001-2002 and 2012-2013 . JAMA Psychiatry (2015) 72 :1235–42. 10.1001/jamapsychiatry.2015.1858 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
3. Carliner H, Brown QL, Sarvet AL, Hasin DS. Cannabis use, attitudes, and legal status in the U.S.: a review . Prev Med . (2017) 104 :13–23. 10.1016/j.ypmed.2017.07.008 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Hyman SM, Sinha R. Stress-related factors in cannabis use and misuse: implications for prevention and treatment . J Subst Abuse Treat . (2009) 36 :400–13. 10.1016/j.jsat.2008.08.005 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Herman JP, Mcklveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. . Regulation of the hypothalamic-pituitary-adrenocortical stress response . Compr Physiol . (2016) 6 :603–21. 10.1002/cphy.c150015 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Lovallo WR. The hypothalamic-pituitary-adrenocortical axis in addiction . Int J Psychophysiol . (2006) 59 :193–4. 10.1016/j.ijpsycho.2005.10.006 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Lovallo WR. Cortisol secretion patterns in addiction and addiction risk . Int J Psychophysiol . (2006) 59 :195–202. 10.1016/j.ijpsycho.2005.10.007 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Mcewen BS. Stress, adaptation, and disease. Allostasis and allostatic load . Ann N Y Acad Sci . (1998) 840 :33–44. 10.1111/j.1749-6632.1998.tb09546.x [PubMed] [CrossRef] [Google Scholar]
9. Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence . Am J Psychiatry (2007) 164 :1149–59. 10.1176/appi.ajp.2007.05030503 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Benowitz NL, Jones RT, Lerner CB. Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral delta-9-tetrahydrocannabinol administration in man . J Clin Endocrinol Metab . (1976) 42 :938–41. 10.1210/jcem-42-5-938 [PubMed] [CrossRef] [Google Scholar]
11. Cone EJ, Johnson RE, Moore JD, Roache JD. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects . Pharmacol Biochem Behav . (1986) 24 :1749–54. 10.1016/0091-3057(86)90515-0 [PubMed] [CrossRef] [Google Scholar]
12. Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR. The effects of 9-ene-tetrahydrocannabinol on hormone release and immune function . J Steroid Biochem . (1989) 34 :263–70. 10.1016/0022-4731(89)90090-3 [PubMed] [CrossRef] [Google Scholar]
13. D’souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T., et al. . Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis . Neuropsychopharmacology (2008) 33 :2505–16. 10.1038/sj.npp.1301643 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
14. Ranganathan M, Braley G, Pittman B, Cooper T, Perry E, Krystal J, et al. . The effects of cannabinoids on serum cortisol and prolactin in humans . Psychopharmacology (2009) 203 :737–44. 10.1007/s00213-008-1422-2 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Kleinloog D, Liem-Moolenaar M, Jacobs G, Klaassen E, De Kam M, Hijman R, et al. Does olanzapine inhibit the psychomimetic effects of Delta(9)-tetrahydrocannabinol? J Psychopharmacol . (2012) 26 :1307–16. 10.1177/0269881112446534 [PubMed] [CrossRef] [Google Scholar]
16. Klumpers LE, Cole DM, Khalili-Mahani N, Soeter RP, Te Beek ET, Rombouts SA, et al. Manipulating brain connectivity with delta(9)-tetrahydrocannabinol: a pharmacological resting state FMRI study . Neuroimage (2012) 63 :1701–11. 10.1016/j.neuroimage.2012.07.051 [PubMed] [CrossRef] [Google Scholar]
17. De Sousa Fernandes Perna EB, Theunissen EL, Kuypers KP, Toennes SW, Ramaekers JG. Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure . Psychopharmacology (2016) 233 :3331–40. 10.1007/s00213-016-4371-1 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Androvicova R, Horacek J, Tintera J, Hlinka J, Rydlo J, Jezova D, et al. . Individual prolactin reactivity modulates response of nucleus accumbens to erotic stimuli during acute cannabis intoxication: an fMRI pilot study . Psychopharmacology (2017) 234 :1933–43. 10.1007/s00213-017-4601-1 [PubMed] [CrossRef] [Google Scholar]
19. Childs E, Lutz JA, De Wit H. Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress . Drug Alcohol Depend . (2017) 177 :136–44. 10.1016/j.drugalcdep.2017.03.030 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Van Leeuwen AP, Creemers HE, Greaves-Lord K, Verhulst FC, Ormel J, Huizink AC. Hypothalamic-pituitary-adrenal axis reactivity to social stress and adolescent cannabis use: the TRAILS study . Addiction (2011) 106 :1484–92. 10.1111/j.1360-0443.2011.03448.x [PubMed] [CrossRef] [Google Scholar]
21. Mcrae-Clark AL, Carter RE, Price KL, Baker NL, Thomas S, Saladin ME, et al. . Stress- and cue-elicited craving and reactivity in marijuana-dependent individuals . Psychopharmacology (2011) 218 :49–58. 10.1007/s00213-011-2376-3 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Somaini L, Manfredini M, Amore M, Zaimovic A, Raggi MA, Leonardi C, et al. . Psychobiological responses to unpleasant emotions in cannabis users . Eur Arch Psychiatry Clin Neurosci . (2012) 262 :47–57. 10.1007/s00406-011-0223-5 [PubMed] [CrossRef] [Google Scholar]
23. Fox HC, Tuit KL, Sinha R. Stress system changes associated with marijuana dependence may increase craving for alcohol and cocaine . Hum Psychopharmacol . (2013) 28 :40–53. 10.1002/hup.2280 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. Tull MT, Mcdermott MJ, Gratz KL. Marijuana dependence moderates the effect of posttraumatic stress disorder on trauma cue reactivity in substance dependent patients . Drug Alcohol Depend . (2016) 159 :219–26. 10.1016/j.drugalcdep.2015.12.014 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
25. Cuttler C, Spradlin A, Nusbaum AT, Whitney P, Hinson JM, Mclaughlin RJ. Blunted stress reactivity in chronic cannabis users . Psychopharmacology (2017) 234 :2299–309. 10.1007/s00213-017-4648-z [PubMed] [CrossRef] [Google Scholar]
26. Nusbaum AT, Whitney P, Cuttler C, Spradlin A, Hinson JM, Mclaughlin RJ. Altered attentional control strategies but spared executive functioning in chronic cannabis users . Drug Alcohol Depend . (2017) 181 :116–23. 10.1016/j.drugalcdep.2017.09.019 [PubMed] [CrossRef] [Google Scholar]
27. Chao T, Radoncic V, Hien D, Bedi G, Haney M. Stress responding in cannabis smokers as a function of trauma exposure, sex, and relapse in the human laboratory . Drug Alcohol Depend . (2018) 185 :23–32. 10.1016/j.drugalcdep.2017.11.021 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
28. Block RI, Farinpour R, Schlechte JA. Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women . Drug Alcohol Depend . (1991) 28 :121–8. 10.1016/0376-8716(91)90068-A [PubMed] [CrossRef] [Google Scholar]
29. King GR, Ernst T, Deng W, Stenger A, Gonzales RM, Nakama H, et al. . Altered brain activation during visuomotor integration in chronic active cannabis users: relationship to cortisol levels . J Neurosci . (2011) 31 :17923–31. 10.1523/JNEUROSCI.4148-11.2011 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
30. Cloak CC, Alicata D, Ernst TM, Chang L. Psychiatric symptoms, salivary cortisol and cytokine levels in young marijuana users . J Neuroimmune Pharmacol . (2015) 10 :380–90. 10.1007/s11481-015-9606-0 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Carol EE, Spencer RL, Mittal VA. The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis . Psychoneuroendocrinology (2017) 83 :58–64. 10.1016/j.psyneuen.2017.04.017 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
32. Lisano JK, Smith JD, Mathias AB, Christensen M, Smoak P, Phillips KT, et al. . Performance and health related characteristics of male athletes using marijuana . J Strength Cond Res . (2017) [Epub ahead of print]. 10.1519/JSC.0000000000002238. [PubMed] [CrossRef] [Google Scholar]
33. Huizink AC, Ferdinand RF, Ormel J, Verhulst FC. Hypothalamic-pituitary-adrenal axis activity and early onset of cannabis use . Addiction (2006) 101 :1581–8. 10.1111/j.1360-0443.2006.01570.x [PubMed] [CrossRef] [Google Scholar]
34. Monteleone P, Di Filippo C, Fabrazzo M, Milano W, Martiadis V, Corrivetti G, et al. . Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure . Psychiatry Res . (2014) 215 :263–7. 10.1016/j.psychres.2013.12.016 [PubMed] [CrossRef] [Google Scholar]
35. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions . J Addict Med . (2011) 5 :1–8. 10.1097/ADM.0b013e31820c23fa [PMC free article] [PubMed] [CrossRef] [Google Scholar]
36. Hunault CC, Bocker KB, Stellato RK, Kenemans JL, De Vries I, Meulenbelt J. Acute subjective effects after smoking joints containing up to 69 mg Delta9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial . Psychopharmacology (2014) 231 :4723–33. 10.1007/s00213-014-3630-2 [PubMed] [CrossRef] [Google Scholar]
37. Murphy LL, Munoz RM, Adrian BA, Villanua MA. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion . Neurobiol Dis . (1998) 5 :432–46. 10.1006/nbdi.1998.0224 [PubMed] [CrossRef] [Google Scholar]
38. Hopfer CJ, Lessem JM, Hartman CA, Stallings MC, Cherny SS, Corley RP, et al. . A genome-wide scan for loci influencing adolescent cannabis dependence symptoms: evidence for linkage on chromosomes 3 and 9 . Drug Alcohol Depend . (2007) 89 :34–41. 10.1016/j.drugalcdep.2006.11.015 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
39. Zorn JV, Schur RR, Boks MP, Kahn RS, Joels M, Vinkers CH. Cortisol stress reactivity across psychiatric disorders: a systematic review and meta-analysis . Psychoneuroendocrinology (2017) 77 :25–36. 10.1016/j.psyneuen.2016.11.036 [PubMed] [CrossRef] [Google Scholar]
40. Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess . Vasc Health Risk Manag . (2005) 1 :291–9. 10.2147/vhrm.2005.1.4.291 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
41. Lupien SJ, De Leon M, De Santi S, Convit A, Tarshish C, Nair NP, et al. . Cortisol levels during human aging predict hippocampal atrophy and memory deficits . Nat Neurosci . (1998) 1 :69–73. 10.1038/271 [PubMed] [CrossRef] [Google Scholar]
42. Pruessner JC, Wolf OT, Hellhammer DH, Buske-Kirschbaum A, Von Auer K, Jobst S, et al. . Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity . Life Sci . (1997) 61 :2539–49. 10.1016/S0024-3205(97)01008-4 [PubMed] [CrossRef] [Google Scholar]
43. Badrick E, Bobak M, Britton A, Kirschbaum C, Marmot M, Kumari M. The relationship between alcohol consumption and cortisol secretion in an aging cohort . J Clin Endocrinol Metab . (2008) 93 :750–7. 10.1210/jc.2007-0737 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
44. Obasi EM, Shirtcliff EA, Brody GH, Mackillop J, Pittman DM, Cavanagh L, et al. . The relationship between alcohol consumption, perceived stress, and CRHR1 genotype on the hypothalamic-pituitary-adrenal axis in rural African Americans . Front Psychol . (2015) 6 :832. 10.3389/fpsyg.2015.00832 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
45. Steiner MA, Wotjak CT. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis . Prog Brain Res . (2008) 170 :397–432. 10.1016/S0079-6123(08)00433-0 [PubMed] [CrossRef] [Google Scholar]
46. Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, Nogue S, et al. . Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings . PLoS ONE (2013) 8 :e55821. 10.1371/journal.pone.0055821 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
47. Yanes JA, Riedel MC, Ray KL, Kirkland AE, Bird RT, Boeving ER, et al. . Neuroimaging meta-analysis of cannabis use studies reveals convergent functional alterations in brain regions supporting cognitive control and reward processing . J Psychopharmacol . (2018) 32 :283–95. 10.1177/0269881117744995 [PMC free article] [PubMed] [CrossRef] [Google Scholar]